|
FY2025
12 months to Dec 31, 2025
|
|
|---|---|
| Net loss | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |
| Stock-based compensation expense | |
| Accretion of discount on investments | |
| Depreciation and amortization | |
| Change in fair value of convertible preferred stock forward | |
| Changes in operating assets and liabilities: | |
| Prepaid expenses and other assets | |
| Accounts payable | |
| Accrued liabilities | |
| Operating lease liabilities | |
| Deferred revenue | |
| Net cash used in operating activities | |
| Cash flows from investing activities: | |
| Purchases of investments | |
| Maturities of investments | |
| Purchase of property and equipment | |
| Net cash used in investing activities | |
| Cash flows from financing activities: | |
| Proceeds from issuance of convertible preferred stock, net of issuance costs | |
| Proceeds from exercise of stock options | |
| Principal payments of finance lease liability | |
| Principal payments of financing obligation | |
| Taxes paid related to net share settlement of equity awards | |
| Net cash provided by financing activities | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | |
| Cash, cash equivalents and restricted cash - beginning of year | |
| Cash, cash equivalents and restricted cash - end of year | |
| Supplemental cash flow disclosures: | |
| Cash paid for interest | |
| Non-cash investing and financing activities: | |
| Issuance of common stock upon conversion of convertible preferred stock | |
| Unpaid fixed asset purchases | |
| Vesting of early exercised stock options | |
| Assets acquired under finance leases | |
| Deferred offering costs in accounts payable | |
| Operating lease liabilities arising from obtaining right-of-use assets | |
| Components of cash, cash equivalents, and restricted cash | |
| Cash and cash equivalents | |
| Restricted cash |
Loading...
